A single center experience with mycophenolate mofetil in the prevention of renal allograft rejection.
Behrend
M
M
Klinik für Abdominal- und Transplantationschirugie, Medizinische Hochschule Hannover, Germany.
Lück
R
R
Köthe
P
P
Pichlmayr
R
R
D000293:Adolescent; D000328:Adult; D000368:Aged; D004311:Double-Blind Method; D005060:Europe; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000401:mortality / Q000517:prevention & control*; D006085:Graft Survival; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010919:Placebos; D011183:Postoperative Complications; D015996:Survival Rate; D013997:Time Factors; D014184:Transplantation, Homologous
D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D010919:Placebos; D009173:Mycophenolic Acid